BenevolentAI SPAC Presentation Deck
BenevolentAl is positioned as a highly recurring drug
generation platform
7
2020
12
2021
2020 - 2030 In-House Pipeline Progression (Not Risk Adjusted)
18
2022
23
2023
29
Source: Company filings and estimates.
2025
Chemistry Pre-Clinical Ph. I Ph. II Ph. III
36
2024
44
2026
54
2027
Commercial
61
2028
71
2029
87
2030
12 named programmes by end
2021 including 1 Phase I/II (Atopic
Dermatitis) and 1 Preclinical
(Ulcerative Colitis)
Building a deep in-house
clinical pipeline with commercial
launches by end of the decade
A platform capable of
delivering 5+ INDS per year from
2024 onwards
ā Supplemented by out-licensed
assets
Platform allows continuous programme generation building a clinical stage pipeline that delivers at scale
Benevolent 34View entire presentation